Table 1.

Associations between the baseline clinicopathological features with OS in bladder metastatic malignant melanoma.

Characteristics		N	%	OS (months)				p Value (Mann-Whitney U test)	p Value (Median test)
				Mean	SD	Compare median (Median test)	IQR
Gender	Female	6	22.2	86.3	28.3	91.0	67.0–100.8	0.137	0.016
	Male	21	77.8	66.8	84.9	21.0	12.0–124.0
Age group	<40	1	3.7	6.0	N/A	6.0	N/A	N/A
	40–49	2	7.4	8.0	9.9	8.0	4.5–11.5
	50–59	4	14.8	48.5	53.9	34.5	16.0–67.0
	60–69	9	33.3	64.0	59.0	38.0	12.0–103.0
	70–79	11	40.7	102.6	93.7	83.0	26.0–142.5
Primary site	Skin	19	70.4	52.3	61.3	23.0	12.5–81.0	0.071	0.164
	Mucosal	8	29.6	118.0	93.2	124.5	67.5–137.3
Bladder tumor No	1	14	51.9	93.7	91.5	71.5	16.5–147.8	0.175	0.123
	≥ 2	9	33.3	37.6	45.4	16.5	12.5–44.5
	Missing	4	14.8	N/A	N/A	N/A	N/A
Synchronous metastasis
Synchronous metastasis	No	7	25.9	117.8	101.9	103.5	56.8–130.0	0.15	0.321
	Yes	20	74.1	58.9	65.2	24.5	11.0–96.3
Lymph node metastasis	Absent	18	66.7	95.1	83.2	83.0	21.0–132.0	0.013	0.134
	Present	9	33.3	29.9	39.9	12.0	6.0–28.0
Extranodal metastasis	Absent	16	59.3	72.2	83.3	38.0	13.5–109.0	0.921	0.873
	Present	11	40.7	73.0	71.8	60.0	14.5–114.0
Widespread	Absent	23	85.2	75.1	79.08	54.0	14.3–118.8	0.973	0.644
	Present	4	14.8	58.8	73.86	29.5	17.8–70.5
Metachronous metastasis
Metachronous metastasis	No	13	48.1	53.1	65.83	24.5	12.5–70.8	0.275	0.175
	Yes	14	51.9	89.2	84.34	85.5	15.0–130.0
Lymph node metastasis	Absent	18	66.7	77.5	86.02	38.0	15.0–124.0	0.837	0.892
	Present	9	33.3	63.2	60.21	48.0	12.0–94.0
Extranodal metastasis	Absent	19	70.4	64.2	82.47	24.5	14.3–86.8	0.253	0.164
	Present	8	29.6	91.4	64.2	109.0	37.5–137.3
Widespread	Absent	24	88.9	64.5	63.83	38.0	13.0–113.5	0.44	0.946
	Present	3	11.1	134.3	151.66	83.0	49.0–194.0
Gross hematuria	No	10	37.0	78.4	70.54	60.5	19.8–117.8	0.558	1.0
	Yes	14	51.9	59.2	54.2	38.0	15.8–99.8
	Missing	3	11.1	N/A	N/A	N/A	N/A